New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
13:21 EDTMNOVMedicNova price target lowered to $6 from $10.50 at Ladenburg
Ladenburg reduced its target on MedicNova after the company indicated that the FDA would require the company to show through a Phase III trial that its asthma treatment reduces hospitalizations. However, the firm continues to be upbeat on the stock and maintains a Buy rating.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
19:04 EDTMNOVMediciNova says CDC supports recruitment for clinical trial of MN-166
Subscribe for More Information
October 22, 2014
19:01 EDTMNOVMediciNova confirmsFDA granted orphan drug designation to MN-001
Subscribe for More Information
07:28 EDTMNOVNortheast Amyotrophic Lateral Sclerosis Consortium to hold annual meeting
Subscribe for More Information
October 21, 2014
18:05 EDTMNOVMediciNova granted orphan status for idiopathic pulmonary fibrosis drug
The FDA posted on its website that MediciNova has been granted orphan status for its treatment of idiopathic pulmonary fibrosis. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use